Navigation Links
AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major milestones in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc. He further stated that, "the work embodied in this patent establishes the 'drugability' of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic."

According to Dr. William Garland, VP & Head of R&D, "both the in vitro and in vivo studies indicate that our small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active." Further, "inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors."

AngioGenex is currently testing a companion diagnostic that detects low levels of the Id proteins in serum. This diagnostic was developed in collaboration with BioCheck, Inc. of Foster City, California. Preliminary clinical results suggest that it has the potential to detect the presence of Id proteins at an early stage of tumor development allowing early medical intervention; it may also be useful to either follow the course of therapy or to determine whether there is a recurrence of disease.

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes o
'/>"/>

SOURCE AngioGenex Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... it has entered into new agreements covering its supply ... the kidney care division of DaVita Healthcare Partners Inc. ... the use of products for home hemodialysis in ... a second amended and restated National Service Provider Agreement ...
(Date:5/21/2013)... 2013   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Operating Officer and Executive Vice President, Finance, will present ... Healthcare Conference on Wednesday, May 29, 2013 at 3:30 ... Westin Boston Waterfront Hotel. The presentation will ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... CHICAGO, Oct. 28 The non-profit Midwest Business Group ... with numerous local and national organizations, have launched a health ... personal contact to help people improve and manage health conditions. ... ) information series will run through the end of ...
... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2
(Date:5/21/2013)... Paris, France: One-year results from SOURCE XT one ... registries to-date reported today at EuroPCR 2013 show ... rates of device success for all access approaches, valve ... Study followed up 2688 consecutively enrolled patients (mean age ... valve at 93 centres in 17 countries between July ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... cuts readmissions , , WEDNESDAY, May 6 (HealthDay News) -- ... airway pressure (CPAP) may help improve outcomes in patients ... CPAP is commonly used to treat sleep apnea. ... Chest , included 232 cardiac surgery patients who ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... outbreak in Mexico, the Foreign and Commonwealth Office (FCO) is advising against ... it will consider all claims for cancelled holidays to the country, scheduled ... ... (PRWEB) -- In the wake of the swine flu outbreak in Mexico, ...
... PHILADELPHIA, May 6 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... exhibitor at the 3rd Annual GlobalFit Worksite Wellness Summit ( ... 14, 2009 at The Down Town Club in Center City ...
... conference focused on promoting physical activity on college ... on connecting health care providers and the public ... infiltrating college campuses nationwide. The American College of ... On Campus," a program component to address and ...
... Against Tobacco Recognized Nationally--WASHINGTON, May 6 ... named Youth Advocates of the Year by the Campaign ... fight against tobacco. Members of REAL are being honored ... the nation,s capital tonight (May 6) along with a ...
Cached Medicine News:Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 3Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 2Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 3Health News:Campaign for Tobacco-Free Kids Honors REAL of Hawai'i As Youth Advocates of the Year 2
Jayle tying forceps, straight....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Medicine Products: